FDA Meets ANDA Backlog Goal Early, Still Doesn't Feel Out Of Woods
Executive Summary
Office of Generic Drugs reviewed more than 90% of official GDUFA backlog of pending applications, but many still will require more work.
You may also be interested in...
'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.
'Bridging' Of Generic Review Goal Dates Makes Progress At US FDA
Assigning official goal dates to ANDAs that hadn't been included in GDUFA began in mid-October and already has lead to approvals.
Generic Manufacturers Try To Up Their Game As US Pressure Persists
With US generic drug price erosion running at double digits, 2017 is expected to be a challenging year for the generic drug sector. Manufacturers are looking increasingly to complex generics, injectables and biosimilars as an offset, but it's unclear if wins in those areas will be enough to bridge the growth divide.